Attention $vitarna token holders/longevity community: 🧬⛓️ New preprint from Weizmann Institute drops a hard truth about longevity: Lifestyle can extend median lifespan — but barely touches maximum lifespan. To break the human ceiling, you must fix damage at its source. 👉 doi.org/10.64898/2025.12.22.… @vitadao @artan_bio @Molecule_sci @Aubrai_

We asked @Aubrai_ to validate the scientific foundation behind @vitarnabio's suppressor tRNA approach for aging. Conclusion: the mechanism is real—CGA→TGA mutations accumulate with age at "order-of-magnitude higher rates" due to CpG hypermutability. Preclinical data shows 6+ months of restored function with minimal off-target effects. Post-chemo patients are ideal: they age faster, carry compounded mutational burden, and we can measure it with epigenetic clocks. The biggest risk isn't the science. It's that no one has run this experiment in humans yet. VitaRNA aims to be first. chat.aubr.ai/chats/TdMWJeN4D…

🧬 A new paper on translation termination & nonsense-mediated decay (NMD) helps explain why arginine nonsense mutations dominate aging and cancer biology. This framework directly supports the biology behind Artan-102. $vitarna @vitadao @vitarnabio @Molecule_sci @BioProtocol pdf.sciencedirectassets.com/…

Attention $vitarna token holders: 🧬 Why mutations matter for aging (and why DeSci should care): This @Nature paper by Cagan et al. shows that somatic mutation rates scale with lifespan across mammals — longer-lived species accumulate mutations more slowly. 👉 nature.com/articles/s41586-0… For $VITARNA holders, this is foundational aging biology. @vitadao @vitarnabio @Molecule_sci @BioProtocol @brian_armstrong

Attention $vitarna tokenholders: New Nature Communications paper shows that protein translation errors increase with age — especially in brain and muscle, but not liver. This matters for anyone thinking about aging, disease, and nonsense mutations. 👉 nature.com/articles/s41467-0… @vitadao @vitarnabio @Molecule_sci @BioProtocol @paulkhls

When we say "suppressor tRNA therapy works," we're not speculating. → Nature: Liu lab proves disease-agnostic protein rescue → Nature Communications: AAV-delivered tRNAs durable for 36+ weeks → Nucleic Acids Research: 16x efficiency gains ARTAN-102 applies the same platform to aging. $VITARNA

Attention $VitaRNA token holders: New Nature paper further supports our work: “Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma” doi.org/10.1038/s41586-025-0… Using deep WGS across >1,000 tumors, this study identifies an endogenous genome-destabilizing program driven by LINE-1 (L1) reactivation that accelerates disease evolution. @vitadao @vitarnabio @Molecule_sci @BioProtocol

Hot take: Most longevity interventions treat downstream symptoms. Senolytics clear damaged cells. NAD+ boosters support metabolism. Rapamycin modulates signaling. ARTAN-102 works at the genetic level—bypassing the nonsense mutations that truncate critical proteins. $VitaRNA

Attention $vitarna token holders: New Nature paper just dropped: ultra-deep sequencing shows that “normal” human tissues are full of cancer-driver mutations, especially after chemo, radiation, and age-related stress. This is the real substrate of aging + cancer risk. nature.com/articles/s41586-0… @vitadao @vitarnabio @Molecule_sci @BioProtocol @Aubrai_

Attention $vitarna token holders: New paper just dropped — worth a read for anyone following longevity biotech & the next wave of DeSci therapeutics. It shows how nonsense & truncating mutations behave inside aging tissues — and why some survive when they shouldn’t. @vitadao @vitarnabio @Molecule_sci @BioProtocol 📄 doi.org/10.1038/s41586-025-0…

Attention $vitarna token holder: A new Nature paper analyzing 1,364 whole cancer genomes shows something striking: nonsense mutations are everywhere, silently shutting off critical proteins long before tumors appear. This is exactly the failure mode Artan-102 is designed to address. nature.com/articles/s41586-0… @vitadao @vitarnabio @Molecule_sci @BioProtocol

Two papers. One conclusion. 🎯 Harvard/Broad used prime editing to permanently install suppressor tRNAs into the genome—correcting premature stop codons in models of Batten disease, Tay-Sachs, cystic fibrosis, and Hurler syndrome without detected readthrough of natural stops. A separate study delivered suppressor tRNAs directly and confirmed the CGA→stop mutation is the most common disease-causing premature termination codon. In a frontotemporal dementia model, they achieved >70% readthrough—outperforming aminoglycosides in efficacy, tolerability, and translation fidelity. Different delivery methods. Same core mechanism: engineered tRNAs that read past premature stops and restore full-length protein. ARTAN-102 uses gene therapy to deliver tRNA suppressors targeting CGA→stop mutations—the same class of variants that accumulate with age in genes tied to DNA repair, tumor suppression, and neurodegeneration. The science is converging. doi.org/10.1038/s41586-025-0… doi.org/10.1093/nar/gkaf730 $VitaRNA

The science keeps aligning. 🤩 New data shows truncated proteins from NMD-escape variants don't just disappear—they accumulate and reshape how cells function as we age. ARTAN-102 targets this directly: read through the premature stop, restore the protein, protect the proteome. Deep dive from our CSO @Mykalt45 👇

Attention $vitarna holders: New paper mapping how nonsense/frameshift mutations actually cause damage just dropped — and it reinforces a key point for aging biology: cells accumulate truncated, mis-wired proteins as we age. This is exactly the class of variants Artan-102 is built to repair. biorxiv.org/content/10.1101/… @vitarnabio @vitadao @Molecule_sci @BioProtocol

Your immune cells age before you do. This Nature study tracked it—T cells reprogram themselves years before you notice anything wrong. That's why older adults struggle with infections and vaccines. ARTAN-102 goes after a specific problem: genetic typos that tell your cells to stop building important proteins too early. $VitaRNA The therapy lets cells read past the typo and finish the job. Community-funded gene therapy. Moving toward IND-enabling studies.

A new Nature study just mapped >16 million immune cells across 300+ people. The punchline: immune aging follows a predictable, programmable transcriptomic drift. Aging is software. Not entropy. @Molecule_sci @vitadao @BioProtocol 🔗 Paper: nature.com/articles/s41586-0…

Update $VITARNA: Received semi-final patent draft, with two additional patents to be completed this week. These filings will help protect our drug development pipeline.

VitaRNA launching $1M fundraise this week 💛 Accelerating IND-enabling studies & advancing RNA therapeutics pipeline 🧬 Join the @vitarnabio telegram for updates t.me/vitarna

So much to unpack…is it worth taking an anti-aging MOA and apply it to a specific disease? Is it possible to design an aging trial that isn’t decades long? These are some of the things we’re taking on with @vitarnabio and @artan_bio. Haven’t raised billions so right stage…

$vitarna cooking